Press Releases

Press Releases concerning clinical trial results are intended to inform interested parties of the advancements of laser technology in process, not to imply new indications for use. Erchonia supports only those indications for use, cleared by the FDA via 510(k).

Erchonia Receives 7th FDA Market Clearance for Non Invasive Fat Loss

Erchonia Receives 7th FDA Market Clearance for Non Invasive Fat Loss

New once a week protocol allows for more treatment flexibility

Erchonia receives patent for noninvasive fat reduction.

Patent no. US 8, 932,338B2- a noninvasive method of reducing fat from targeted regions of a patient's body by applying low-level laser energy externally through the skin of the patient to the targeted areas. The laser works by applying sufficient energy to release intracellular fat into the interstitial space. The released intra-cellular fat is removed through the body's natural functions.

FDA Clears Erchonia’s New FX635 Laser for Chronic Heel Pain from Plantar Fasciitis

Erchonia today announces the U.S. Food and Drug Administration (FDA) has granted the company 510 (k) clearance to market FX635, its new low level laser for the relief of chronic heel pain from plantar fasciitis. Clearance was based on a double-blind, randomized, multi-site and placebo-controlled clinical trial.  

McKinney, TX (PRWEB) April 22, 2014

Results of Erchonia’s Lunula Laser’s Clinical Trial for the Noninvasive Treatment of Nail Fungus Published in Podiatry Review

Erchonia today announces that the preliminary results of an ongoing clinical trial testing its Lunula laser for the noninvasive treatment of nail fungus have been published in the latest issue of the medical journal Podiatry Review.

Erchonia Expands Presence in Europe with Erchonia Laser Ltd.

McKinney, TX – November 5, 2013 – Erchonia, the global leader in low level laser healthcare applications, today announces the company is expanding with a London-based team, Erchonia Laser Ltd.

Erchonia XLR8 Laser Granted FDA Clearance for Pain Treatment

Contact: Katie Cycan
Crier Communications
310-274-1072 x 207

Erchonia XLR8 Laser Granted FDA Clearance for Pain Treatment

Harvard Scientists Commend Erchonia for Excellence in Clinical Research for the Zerona Laser

Tuesday, August 6th 2013
In the latest volume of the medical journal, Lasers in Surgery and Medicine, three Harvard scientists concluded that Erchonia’s research for its Zerona low-level laser device has, "set the precedent on how aesthetic devices should be evaluated."
McKinney, TX (PRWEB) August 06, 2013